Small Nuclear RNAs (U1, U2, U5) in Tumor-Educated Platelets Are Downregulated and Act as Promising Biomarkers in Lung Cancer

Dong, Xiaohan; Ding, Shanshan; Yu, Miao; Niu, Limin; Xue, Linlin; Zhao, Yajing; Xie, Li; Song, Xingguo

doi:10.3389/fonc.2020.01627

Cited by 29 publications

(38 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, our study and others have also demonstrated miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p in plasma act as novel biomarkers in the early diagnosis of NSCLC patients. Notably, our group and others have identified kinds of non‐coding RNAs in circulation, which also serve as promising biomarkers for lung cancer, such as lncRNAs, 29 tumor educated platelet small nuclear RNAs (snRNAs) 30 and exosomal miRNAs, 31 indicating the complex mechanisms involved in the tumorigenesis of lung cancer. Combined detection of these kinds of non‐coding RNAs might be a shortcut to increase the accuracy of the diagnoses of lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Accumulating evidence shows that microRNAs are aberrantly expressed and exert essential roles in the tumorigenesis and tumor progression of non‐small cell lung cancer (NSCLC). Methods The plasma miRNAs from five healthy donors and four NSCLC patients were profiled by miRNA microarray. The differentially expressed miRNAs from 154 primary NSCLC patients and 146 healthy donors were subjected to RNA isolation and verified by quantitative PCR (qPCR). Results The miRNA microarray analysis revealed that 40 differential miRNAs between NSCLC patients and healthy donors were selected. We found that the plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p levels of patients were significantly higher than those of healthy controls. The receiver operating characteristic curve (ROC) analyses revealed higher area under the ROC curve (AUC) values and higher sensitivity/specificity of carcinoembryonic antigen (CEA) in combination with miR‐1247‐5p, miR‐301b‐3p, or miR‐105‐5p were superior to that of CEA alone. Conclusions High miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p expression have been demonstrated to accelerate tumorigenesis, and these three miRNAs in plasma act as novel biomarkers for the early diagnosis of NSCLC patients. Key points Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p act as novel biomarkers for early NSCLC and NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to current studies, ncRNAs, especially miRNAs, lncRNAs and circRNAs, play crucial roles in regulating AS. Recently, snRNAs (U1, U2, U4, U5, and U6) have also been shown to act as regulators of AS in cancer, in addition to basal factors of the spliceosome [ 41 , 42 ]. In the following sections, we further discuss the specific regulatory relationships between ncRNAs and AS in cancers.…”

Section: Noncoding Rnas In Alternative Splicingmentioning

confidence: 99%

“…ISEs and ISSs represent intronic splicing enhancers and silencers, respectively. SR proteins, hnRNPs, or other transacting factors bind to cis-acting elements for positive or negative AS regulation by affecting the recruitment or recognition of spliceosome components to splice sites; for example, U1 binds to the 5′ splice site, while U2AF and U2 bind to the 3′ splice site have also been shown to act as regulators of AS in cancer, in addition to basal factors of the spliceosome [41,42]. In the following sections, we further discuss the specific regulatory relationships between ncRNAs and AS in cancers.…”

Section: Noncoding Rnas In Alternative Splicingmentioning

confidence: 99%

Noncoding RNAs regulate alternative splicing in Cancer

Liu

Lin

et al. 2021

J Exp Clin Cancer Res

101

View full text Add to dashboard Cite

AS (alternative splicing) is a fundamental process by which a gene can generate multiple distinct mRNA transcripts to increase protein diversity. Defects in AS influence the occurrence and development of many diseases, including cancers, and are frequently found to participate in various aspects of cancer biology, such as promoting invasion, metastasis, apoptosis resistance and drug resistance. NcRNAs (noncoding RNAs) are an abundant class of RNAs that do not encode proteins. NcRNAs include miRNAs (microRNAs), lncRNAs (long noncoding RNAs), circRNAs (circular RNAs) and snRNAs (small nuclear RNAs) and have been proven to act as regulatory molecules that mediate cancer processes through AS. NcRNAs can directly or indirectly influence a plethora of molecular targets to regulate cis-acting elements, trans-acting factors, or pre-mRNA transcription at multiple levels, affecting the AS process and generating alternatively spliced isoforms. Consequently, ncRNA-mediated AS outcomes affect multiple cellular signaling pathways that promote or suppress cancer progression. In this review, we summarize the current mechanisms by which ncRNAs regulate AS in cancers and discuss their potential clinical applications as biomarkers and therapeutic targets.

show abstract

“…Small nuclear RNAs (snRNAs) of the spliceosome are the basal factors and present in platelets, as they are required for splicing 17 . In our previous study, we reported snRNAs (U1, U2, U5) in TEPs are downregulated and act as promising biomarkers in lung cancer, indicating their contribution to the specific spliced mRNA signature in TEPs 18 . In the anucleated platelets, snoRNAs might more likely regulate the alternative splicing of pre‐mRNA by competing with snRNP other than direct modification to snRNA 19 .…”

Section: Introductionmentioning

confidence: 99%

Tumor‐educated platelet SNORD55 as a potential biomarker for the early diagnosis of non‐small cell lung cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Despite the emerging insights into many snoRNAs (small nucleolar RNAs) which are detectable in body fluids and serve as noninvasive biomarkers, few studies have previously discussed the role of snoRNAs in tumor‐educated platelets (TEPs). Herein, we systematically estimated dysregulation of snoRNAs in non‐small cell lung cancer (NSCLC) and clarified the biomarker potential of SNORD55 in platelets. Methods We compared expression of snoRNAs between NSCLC and normal tissues using SNORic datasets. Platelets were isolated from plasma using low‐speed centrifugation and subjected to quantitative polymerase chain reaction (qPCR) for SNORD55 detection. Results SNORD55 was significantly decreased in TEPs from NSCLC patients especially in early‐stage patients compared with healthy controls. Importantly, we validated that TEP SNORD55 was capable of acting as a promising biomarker for NSCLC. It exerted diagnostic performance for NSCLC diagnosis, possessing an AUC of 0.803, as well as for early NSCLC diagnosis, possessing an AUC of 0.784. Moreover, the combination of TEP SNORD55 and carcinoembryonic antigen (CEA) improved the diagnostic efficiency of cancer progression. In addition, TEP SNORD55 also potentially acts as a noninvasive early biomarker for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) with favorable diagnostic efficiencies. Conclusions In summary, TEP SNORD55 could potentially serve as a noninvasive biomarker for NSCLC diagnosis and early diagnosis. Key points SNORD55 was significantly decreased in TEPs from NSCLC patients compared to healthy controls and acted as a novel biomarker for early NSCLC.

show abstract

Small Nuclear RNAs (U1, U2, U5) in Tumor-Educated Platelets Are Downregulated and Act as Promising Biomarkers in Lung Cancer

Cited by 29 publications

References 32 publications

Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer

Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer

Noncoding RNAs regulate alternative splicing in Cancer

Tumor‐educated platelet SNORD55 as a potential biomarker for the early diagnosis of non‐small cell lung cancer

Contact Info

Product

Resources

About